A retrospective study on clinical and Para clinical findings of Quetiapine toxicity cases admitted in Clinical Toxicology Center, Imam Reza Hospital for five years

Articles in Press

Document Type : Original Article

Authors

1 Mashhad University of Medical Sciences, Mashhad, Iran

2 Medical Toxicology Research Center, Faculty of Medicine, Mashhad University of medical sciences, Mashhad, Iran

3 Department of Internal Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background: Quetiapine is a dibenzothiazepine-derived antipsychotic drug that has been evaluated for the management of patients with psychotic disorders. Quetiapine is associated with an increased risk of death in dementia-related psychosis in elderly patients. There is a risk of increased suicidal thoughts and behavior associated with drug treatment in patients with major depressive disorder.

Objectives: Our study aims to investigate the patients with quetiapine poisoning within 5 years.

Methods: The files of patients who were poisoned by antipsychotic drugs during the study period were collected at the poisoning department of Imam Reza Hospital. Those who reported poisoning with Quetiapine were included in the study and analyzed. The checklist was prepared in advance, and information was entered into it. Based on the normality or not of the data distribution, parametric and non-parametric tests were used, and SPSS was used to analyze the data.

Results: The number of 31 cases was related to patients who registered poisoning with Quetiapine; 15 were male (48.38%), and 16 were female (51.61%). The average age of the patients was 45.25±35.51, and the average total dose consumed was 745.85±242.65. Also (64.51%) were discharged from the hospital with full or partial recovery, and no deaths were reported. Also, the average dose consumed had a significant relationship with QTC, WBC, level of consciousness, heart rate, and outcome (P<0.05), while no significant relationship was observed with other variables.

Conclusion: According to the present study, Quetiapine has many side effects, the most being cardiovascular complications, which show the need for special clinical care related to the heart and blood vessels.

Keywords

Acknowledgment: The authors would like to express their gratitude to all the Study participants for their cooperation. We also thank the Clinical Research Development Centre, Imam Reza Hospital, Mashhad University of Medical Sciences, for assisting with this manuscript. This work was supported by Research Project No. 980323, financed by Mashhad University of Medical Sciences.

 

Availability of data and materials: The dataset analyzed during the current study is available upon reasonable request from the corresponding author.

 

Conflicts of interests: The authors have no relevant conflict interests to declare.

 

Consent for publication: not application.

 

Ethics approval and consent to participate: The Ethics Committee of Mashhad University of Medical Sciences approved the study (IR.Mums.Medical.REC.1398.453). The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. writing Informed consent was also obtained. Confidentiality of participant information was strictly maintained, with no personal identifiers (such as names or surnames) entered into the software. All individuals were assigned a unique project code, and analyses were conducted based on these anonymized identifiers. The primary investigator retained the original data until project completion and article publication, ensuring data security throughout the study.


Financial disclosure: No financial support was received for this study.

 

Author contributions: Authors MSH, BD andZA T designed the study. MSH, BD andZA participated in the conception of the study. MSH and BD managed and conducted thestatistical analyses and interpreted the data.All authors have read and approved the final manuscrip.

 

Open Access Policy: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/

References

1. Caponi S. On the so-called psychopharmacological revolution: the discovery of chlorpromazine and the management of madness. História, Ciências, Saúde-Manguinhos. 2021;28:661-83.
https://doi.org/10.1590/s0104-59702021000300003
PMid:34495111
 
2. Orzelska-Górka J, Mikulska J, Wiszniewska A, Biała G. New atypical antipsychotics in the treatment of schizophrenia and depression. International Journal of Molecular Sciences. 2022;23(18):10624.
https://doi.org/10.3390/ijms231810624
PMid:36142523 PMCid:PMC9500595  
 
3. Lin C-Y, Chiang C-H, Tseng M-CM, Tam K-W, Loh E-W. Effects of Quetiapine on sleep: a systematic review and meta-analysis of clinical trials. European Neuropsychopharmacology. 2023;67:22-36.
https://doi.org/10.1016/j.euroneuro.2022.11.008
PMid:36463762  
 
4. Early M, Wink L, Erickson CA, McDougle CJ. Quetiapine. Encyclopedia of Autism Spectrum Disorders: Springer; 2021. p. 3826-.
https://doi.org/10.1007/978-3-319-91280-6_838  
 
5. Fabrazzo M, Cipolla S, Camerlengo A, Perris F, Catapano F. Second-generation antipsychotics' effectiveness and tolerability: a review of real-world studies in patients with schizophrenia and related disorders. Journal of Clinical Medicine. 2022;11(15):4530.
https://doi.org/10.3390/jcm11154530
PMid:35956145 PMCid:PMC9369504  
 
6. Mutwalli H, Keeler JL, Bektas S, Dhopatkar N, Treasure J, Himmerich H. Eating cognitions, emotions and behaviour under treatment with second-generation antipsychotics: a systematic review and meta-analysis. Journal of psychiatric research. 2023;160:137-62.
https://doi.org/10.1016/j.jpsychires.2023.02.006
PMid:36804110 PMCid:PMC10682412  
 
7. Evoy KE, Humpert S, Torrez S, Hussein H, Covvey JR. Quetiapine and olanzapine misuse prevalence in a US general population sample. Mental Health Clinician. 2023;13(2):25-35.
https://doi.org/10.9740/mhc.2023.04.025
PMid:37063941 PMCid:PMC10094996  
 
8. Gupta A, Kumar Y, Zaheer MR, Roohi, Iqbal S, Iqbal J. Electron transfer-mediated photodegradation of phototoxic antipsychotic drug quetiapine. ACS omega. 2021;6(45):30834-40.
https://doi.org/10.1021/acsomega.1c05302
PMid:34805712 PMCid:PMC8600633  
 
9. Dharkiya S, Rukayya, Nandi S, editors. Pharmacophore Modeling of Tricyclic Antipsychotics. International Symposium on Global Trends in Health, Technology and Management; 2024: Springer.
https://doi.org/10.1007/978-3-031-75457-9_19  
 
10. Højlund M, Andersen K, Ernst MT, Correll CU, Hallas J. Use of low‐dose Quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator‐controlled cohort study. World Psychiatry. 2022;21(3):444-51.
https://doi.org/10.1002/wps.21010
PMid:36073694 PMCid:PMC9453914  
 
11. Bisht M. Sleep During Hypnotic Therapy. Sleep and Neuropsychiatric Disorders. 2022:793-809.
https://doi.org/10.1007/978-981-16-0123-1_39  
 
12. Dubath C, Piras M, Gholam M, Laaboub N, Grosu C, Sentissi O, et al. Effect of Quetiapine, from low to high dose, on weight and metabolic traits: results from a prospective cohort study. Pharmacopsychiatry. 2021;54(06):279-86.
https://doi.org/10.1055/a-1525-2820
PMid:34388836  
 
13. Højlund M, Støvring H, Andersen K, Correll CU, Hallas J. Impact of low‐dose quetiapine‐use on glycosylated hemoglobin, triglyceride and cholesterol levels. Acta Psychiatrica Scandinavica. 2023;147(1):105-16.
https://doi.org/10.1111/acps.13515
PMid:36281759 PMCid:PMC10099591  
 
14. Breivik H, Westin AA, Frost J. Doses, serum concentrations and diagnoses of Norwegian quetiapine users 2001-2019 in a therapeutic drug monitoring material. Basic & Clinical Pharmacology & Toxicology. 2024;135(4):523-33.
https://doi.org/10.1111/bcpt.14074
PMid:39219150  
 
15. Dobravc Verbič M, Grabnar I, Eyer F, Brvar M. Acute Quetiapine Intoxication: Relationship Between Ingested Dose, Serum Concentration and Clinical Presentation-Structured Literature Review and Analysis. Journal of Xenobiotics. 2024;14(4):1570-94.
https://doi.org/10.3390/jox14040085
PMid:39449426 PMCid:PMC11503392  
 
16. Rudå D, Jensen KG, Decara MS, Klauber DG, Fagerlund B, Møllegaard JR, et al. CYP2D6 genotyping and antipsychotic-associated extrapyramidal adverse effects in a randomized trial of aripiprazole versus Quetiapine extended release in children and adolescents, aged 12-17 years, with first episode psychosis. Journal of Clinical Psychopharmacology. 2021;41(6):667-72.
https://doi.org/10.1097/JCP.0000000000001490
PMid:34735099  
 
17. Monahan K, Cuzens-Sutton J, Siskind D, Kisely S. Quetiapine withdrawal: A systematic review. Australian & New Zealand Journal of Psychiatry. 2021;55(8):772-83.
https://doi.org/10.1177/0004867420965693
PMid:33059460  
 
18. Cobilinschi C, Mirea L, Andrei C-A, Ungureanu R, Cotae A-M, Avram O, et al. Biodetoxification using intravenous lipid emulsion, a rescue therapy in life-threatening Quetiapine and venlafaxine poisoning: a case report. Toxics. 2023;11(11):917.
https://doi.org/10.3390/toxics11110917
PMid:37999569 PMCid:PMC10675033  
 
19. Hall KF, Korona-Bailey J, Lazar M, Onyango E, Mukhopadhyay S. Understanding Quetiapine's Involvement in Fatal and Nonfatal Drug Overdoses, Tennessee 2019-2022. International Journal of Mental Health and Addiction. 2025:1-14.
https://doi.org/10.1007/s11469-024-01439-1  
 
20. Müller C, Reuter H, Dohmen C. Intoxication after extreme oral overdose of Quetiapine to attempt suicide: pharmacological concerns of side effects. Case reports in medicine. 2009;2009(1):371698
https://doi.org/10.1155/2009/371698
https://doi.org/10.1055/s-0029-1240177
PMid:20066171  
Razavi International Journal of Medicine

Articles in Press, Accepted Manuscript
Available Online from 18 May 2025

Files

Share

How to cite

Statistics